Daniel Devine & Co held its stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, Holdings Channel reports. The firm owned 45,144 shares of the company’s stock at the end of the second quarter. Zoetis comprises 1.5% of Daniel Devine & Co’s holdings, making the stock its 18th largest position. Daniel Devine & Co’s holdings in Zoetis were worth $2,143,000 as of its most recent filing with the SEC.
Other large investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in Zoetis by 398.6% in the first quarter. Renaissance Technologies LLC now owns 1,413,100 shares of the company’s stock worth $62,643,000 after buying an additional 1,129,700 shares in the last quarter. Cullen Frost Bankers Inc. boosted its stake in Zoetis by 0.7% in the second quarter. Cullen Frost Bankers Inc. now owns 347,368 shares of the company’s stock worth $16,486,000 after buying an additional 2,470 shares in the last quarter. Legal & General Group Plc boosted its stake in Zoetis by 0.9% in the first quarter. Legal & General Group Plc now owns 2,104,616 shares of the company’s stock worth $93,293,000 after buying an additional 18,063 shares in the last quarter. York Capital Management Global Advisors LLC purchased a new stake in Zoetis during the first quarter worth $49,823,000. Finally, Raymond James Trust N.A. boosted its stake in Zoetis by 5.0% in the second quarter. Raymond James Trust N.A. now owns 5,909 shares of the company’s stock worth $281,000 after buying an additional 281 shares in the last quarter. Institutional investors and hedge funds own 93.14% of the company’s stock.
Shares of Zoetis Inc. (NYSE:ZTS) traded up 2.06% on Tuesday, hitting $51.06. The company had a trading volume of 2,032,614 shares. Zoetis Inc. has a 12-month low of $38.26 and a 12-month high of $53.14. The company has a market cap of $25.28 billion, a price-to-earnings ratio of 39.77 and a beta of 1.00. The company has a 50 day moving average of $51.23 and a 200-day moving average of $49.13.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.05. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.43 earnings per share. On average, analysts forecast that Zoetis Inc. will post $1.91 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Thursday, November 3rd will be given a $0.095 dividend. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 annualized dividend and a yield of 0.74%. Zoetis’s dividend payout ratio (DPR) is 29.69%.
ZTS has been the topic of a number of research reports. Jefferies Group restated a “buy” rating and issued a $60.00 price target on shares of Zoetis in a report on Wednesday, September 14th. Zacks Investment Research cut Zoetis from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. Bank of America Corp. started coverage on Zoetis in a report on Thursday, September 29th. They set a “buy” rating and a $60.00 target price on the stock. Guggenheim reiterated a “positive” rating and set a $60.00 target price on shares of Zoetis in a report on Monday, August 22nd. Finally, Citigroup Inc. increased their target price on Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a report on Thursday, August 4th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Zoetis presently has a consensus rating of “Buy” and a consensus target price of $55.50.
In other news, Director Michael B. Mccallister acquired 2,000 shares of the stock in a transaction on Tuesday, September 6th. The shares were purchased at an average cost of $51.34 per share, for a total transaction of $102,680.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Heidi C. Chen sold 32,097 shares of Zoetis stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the transaction, the insider now owns 46,060 shares in the company, valued at $2,348,138.80. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.